SB
ALXN

Suntrust Banks’s Alexion Pharmaceuticals ALXN Stock Holding History

Suntrust Banks’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$875K Sell
8,927
-10,928
-55% -$1.23M ﹤0.01% 782
2019
Q2 		$2.6M Sell
19,855
-1,172
-6% -$151K 0.01% 513
2019
Q1 		$2.84M Buy
21,027
+3,289
+19% +$409K 0.02% 464
2018
Q4 		$1.73M Sell
17,738
-2,977
-14% -$352K 0.01% 562
2018
Q3 		$2.88M Buy
20,715
+1,273
+7% +$160K 0.01% 446
2018
Q2 		$2.41M Sell
19,442
-565
-3% -$66K 0.01% 487
2018
Q1 		$2.23M Buy
20,007
+4,982
+33% +$595K 0.01% 497
2017
Q4 		$1.8M Sell
15,025
-14,373
-49% -$1.75M 0.01% 550
2017
Q3 		$4.12M Buy
29,398
+176
+0.6% +$23.9K 0.02% 343
2017
Q2 		$3.56M Buy
29,222
+2,389
+9% +$278K 0.02% 349
2017
Q1 		$3.25M Sell
26,833
-3,129
-10% -$403K 0.02% 351
2016
Q4 		$3.67M Sell
29,962
-3,125
-9% -$382K 0.02% 355
2016
Q3 		$4.05M Buy
33,087
+659
+2% +$84.8K 0.03% 334
2016
Q2 		$3.79M Sell
32,428
-4,322
-12% -$613K 0.02% 333
2016
Q1 		$5.12M Buy
36,750
+1,096
+3% +$161K 0.03% 263
2015
Q4 		$6.8M Buy
35,654
+20,240
+131% +$3.54M 0.04% 229
2015
Q3 		$2.41M Sell
15,414
-1,042
-6% -$190K 0.02% 376
2015
Q2 		$2.97M Sell
16,456
-1,881
-10% -$325K 0.02% 344
2015
Q1 		$3.18M Sell
18,337
-40
-0.2% -$7.24K 0.02% 322
2014
Q4 		$3.4M Sell
18,377
-8,309
-31% -$1.54M 0.02% 304
2014
Q3 		$4.42M Sell
26,686
-3,161
-11% -$519K 0.03% 273
2014
Q2 		$4.66M Sell
29,847
-209,385
-88% -$33.1M 0.03% 277
2014
Q1 		$36.4M Sell
239,232
-106,022
-31% -$16.9M 0.13% 221
2013
Q4 		$45.9M Sell
345,254
-7,042
-2% -$845K 0.18% 185
2013
Q3 		$40.9M Sell
352,296
-55,750
-14% -$6.12M 0.16% 199
2013
Q2 		$37.6M Buy
+408,046
New +$39.3M 0.17% 189

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Suntrust Banks's ALXN Position: Q3 2019 in Review

Suntrust Banks reduced its Alexion Pharmaceuticals (ALXN) stake by 55% in Q3 2019, selling an estimated $1.23M and leaving 8,927 shares worth $875K. The position accounts for ﹤0.01% of the portfolio, ranked #782.

Suntrust Banks first reported a position in ALXN in Q2 2013 and has held it in 26 quarters since. The position peaked at $45.9M in Q4 2013. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Suntrust Banks held 8,927 shares of Alexion Pharmaceuticals worth $875K as of Q3 2019.
  • Suntrust Banks sold 10,928 Alexion Pharmaceuticals shares in Q3 2019, an estimated $1.23M.
  • Alexion Pharmaceuticals made up ﹤0.01% of Suntrust Banks's portfolio in Q3 2019, its #782 holding.
  • Suntrust Banks first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • Suntrust Banks's Alexion Pharmaceuticals position peaked at $45.9M in Q4 2013.
  • 647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Suntrust Banks's 13F filing for Q3 2019, filed 12 Nov 2019.